dc.contributor.author | Bostancıoğlu, R. Beklem | |
dc.contributor.author | Koparal, Ayşe Tansu | |
dc.contributor.author | Benkli, Kadriye | |
dc.date.accessioned | 2019-10-20T08:00:00Z | |
dc.date.available | 2019-10-20T08:00:00Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 1382-6689 | |
dc.identifier.issn | 1872-7077 | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.etap.2014.03.003 | |
dc.identifier.uri | https://hdl.handle.net/11421/15900 | |
dc.description | WOS: 000338598200001 | en_US |
dc.description | PubMed ID: 24694919 | en_US |
dc.description.abstract | Around the world scientists try to design successful cures against still incurable diseases, especially cancers. New targets for prevention and new agents for therapy need to be identified. We synthesized novel metal complexes [Au(L1)(L2)Pt]Cl2 and [Ru(L1)2(L2)Pt]Cl2 for determining their cytotoxic and apoptotic effects. The complexes are synthesized by using 1,8-diaminonaphthalene (L1), and bis-1,4-di[([1,10]phenanthroline-5-il)aminomethyl]cyclohexane (L2) as ligands. This is the first study to examine these metals and these molecules in cancer treatment. We elucidated the effects of test compounds with embryonic rat fibroblast-like cells (F2408) and H-ras oncogene activated embryonic rat fibroblast-like cancer cells (5RP7). Results showed that our complexes are more effective than cisplatin to kill ras-transformed cells. Although the [Au(L1)(L2)Pt]Cl2 compound showed a cytotoxic potency higher than [Ru(L1)2(L2)Pt]Cl2 against cancer cells, it proved to be almost five times less effective in decreasing cell viability over healthy cells. Au(III) compound selectively targets the cancer cells but not the healthy cells | en_US |
dc.description.sponsorship | Scientific and Technological Research Council of Turkey [TUBITAK-SBAG-108S206]; NOVARTISNovartis; Anadolu University, Commission of Scientific Research Projects [070304] | en_US |
dc.description.sponsorship | This work was financed by a grant from the Scientific and Technological Research Council of Turkey (TUBITAK-SBAG-108S206) and NOVARTISNovartis (2007 Novartis Pharmaceutical and Medicinal Chemistry Drug Design and Development Research Support). The authors are grateful to Anadolu University, Commission of Scientific Research Projects for financial support to Project 070304. Authors also thank deeply to Assoc. Prof. Dr. Caghan Kizil (Helmholtz Association, German Center for Neurodegenerative Diseases (DZNE) Dresden, Germany) for proof-reading of the manuscript. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Science BV | en_US |
dc.relation.isversionof | 10.1016/j.etap.2014.03.003 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Au(Iii) | en_US |
dc.subject | Ru(Ii) | en_US |
dc.subject | Pt(Ii) | en_US |
dc.subject | Antitumoral Activity | en_US |
dc.subject | Apoptosis | en_US |
dc.subject | Selective Toxicity | en_US |
dc.title | Investigation of the pharmacological profiles of dinuclear metal complexes as novel, potent and selective cytotoxic agents against leas-transformed cells | en_US |
dc.type | article | en_US |
dc.relation.journal | Environmental Toxicology and Pharmacology | en_US |
dc.contributor.department | Anadolu Üniversitesi, Fen Fakültesi, Biyoloji Bölümü | en_US |
dc.identifier.volume | 37 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 897 | en_US |
dc.identifier.endpage | 906 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.contributor.institutionauthor | Koparal, Ayşe Tansu | |
dc.contributor.institutionauthor | Benkli, Kadriye | |